Joseph Piscitelli1, Mina Nikanjam1, Brookie M Best1, Edward Acosta2, Mark Mirochnick3, Diana F Clarke4, Edmund V Capparelli1, Jeremiah D Momper1. 1. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA. 2. Department of Pharmacology, University of Alabama Birmingham, Birmingham, AL. 3. Department of Pediatrics, Boston University School of Medicine, Boston, MA; and. 4. Section of Pediatrics Infectious Diseases, Boston Medical Center, Boston, MA.
Abstract
BACKGROUND: A knowledge gap exists for dolutegravir (DTG) pharmacokinetics and safety during the first 4 weeks of life, preventing safe and effective DTG use in neonates. SETTING: Population pharmacokinetic modeling and simulation were used to assess newborn DTG dosing requirements during the first few days of life as a function of maternal DTG dosing history before delivery. METHODS: DTG PK data were obtained from pregnant women and infants enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026S study. Maternal and neonate population pharmacokinetic models were separately developed. Monte Carlo simulations were performed to simulate neonatal concentrations after 2 doses of DTG after birth for infants born to mothers either receiving or not receiving DTG before delivery. RESULTS: In DTG-naïve infants, a 5-mg DTG dose at birth with a second dose after 48 hours maintained median concentrations above the lower bound of the target range (0.77 μg/mL) and below the upper bound of the target range (7.34 μg/mL representing 2-fold above the adult Cmax value). In DTG-exposed infants, a 5-mg DTG dose at 24 hours after birth with a second dose after 48 hours maintained median concentrations within or nearly within the target range, even if the last maternal DTG dose was taken as soon as 6 hours or as long as 24 hours before delivery. CONCLUSIONS: Newborn DTG dosing requirements during the first few days of life depend on maternal DTG dosing history before delivery. These results may help the design of future clinical studies of DTG in the neonatal population.
BACKGROUND: A knowledge gap exists for dolutegravir (DTG) pharmacokinetics and safety during the first 4 weeks of life, preventing safe and effective DTG use in neonates. SETTING: Population pharmacokinetic modeling and simulation were used to assess newborn DTG dosing requirements during the first few days of life as a function of maternal DTG dosing history before delivery. METHODS: DTG PK data were obtained from pregnant women and infants enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026S study. Maternal and neonate population pharmacokinetic models were separately developed. Monte Carlo simulations were performed to simulate neonatal concentrations after 2 doses of DTG after birth for infants born to mothers either receiving or not receiving DTG before delivery. RESULTS: In DTG-naïve infants, a 5-mg DTG dose at birth with a second dose after 48 hours maintained median concentrations above the lower bound of the target range (0.77 μg/mL) and below the upper bound of the target range (7.34 μg/mL representing 2-fold above the adult Cmax value). In DTG-exposed infants, a 5-mg DTG dose at 24 hours after birth with a second dose after 48 hours maintained median concentrations within or nearly within the target range, even if the last maternal DTG dose was taken as soon as 6 hours or as long as 24 hours before delivery. CONCLUSIONS: Newborn DTG dosing requirements during the first few days of life depend on maternal DTG dosing history before delivery. These results may help the design of future clinical studies of DTG in the neonatal population.
Authors: Robin Kobbe; Stein Schalkwijk; Gabor Dunay; Johanna M Eberhard; Ulf Schulze-Sturm; Bettina Hollwitz; Olaf Degen; Marga Teulen; Angela Colbers; David Burger Journal: AIDS Date: 2016-11-13 Impact factor: 4.177
Authors: Cynthia N Schreiner; Charles E Ahlfors; Ronald J Wong; David K Stevenson; Diana F Clarke; Mark Mirochnick Journal: Pediatr Infect Dis J Date: 2018-09 Impact factor: 2.129
Authors: Diana F Clarke; Mark Mirochnick; Edward P Acosta; Edmund Capparelli; Anne Chain; Hedy Teppler; Betsy Smith; Jos Lommerse Journal: J Acquir Immune Defic Syndr Date: 2019-12-01 Impact factor: 3.731